Showing results (31-40 of 56) with videos related to

Sort By:
Pageof 6
Clinical Colorectal Cancer|February 12, 2014
A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancersCrystal S Denlinger, Neal J Meropol, Tianyu Li, et al.
Cancer Chemotherapy and Pharmacology|February 5, 2004
Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancerSteven J Cohen, James Gallo, Nancy L Lewis, et al.
Cancer Immunology, Immunotherapy : CII|August 16, 2011
Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatmentShangzi Wang, Igor A Astsaturov, Catherine A Bingham, et al.
Breast Cancer Research and Treatment|June 18, 2017
A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)Lori J Goldstein, Fengmin Zhao, Molin Wang, et al.
International Journal of Molecular Sciences|February 21, 2020
Genetic Variants Detected Using Cell-Free DNA from Blood and Tumor Samples in Patients with Inflammatory Breast CancerJennifer S Winn, Zachary Hasse, Michael Slifker, et al.
Gynecologic Oncology|June 20, 2012
Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group studyRussell J Schilder, William E Brady, Heather A Lankes, et al.
Cancer Letters|September 5, 2025
Phenotyping and Clinical Utility of Phagocytic Polyploid Giant Cancer Macrophages in BloodDaniel L Adams, Massimo Cristofanilli, Steven H Lin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 14, 2012
Biodistribution and radiation dosimetry of the integrin marker 18F-RGD-K5 determined from whole-body PET/CT in monkeys and humansMohan Doss, Hartmuth C Kolb, James J Zhang, et al.
Breast Cancer Research and Treatment|June 7, 2014
A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancerYifan Tu, Dawn L Hershman, Kapil Bhalla, et al.
Elife|February 1, 2017
Matrix-regulated integrin αvβ5 maintains α5β1-dependent desmoplastic traits prognostic of neoplastic recurrenceJanusz Franco-Barraza, Ralph Francescone, Tiffany Luong, et al.
Pageof 6